Pliant Therapeutics Inc (PLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.23 Million) by net assets ($165.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Pliant Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Pliant Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Pliant Therapeutics Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CONCORD ENVIRO SYSTEMS L
NSE:CEWATER
|
-0.074x |
|
Transindia Real Estate Limited
NSE:TREL
|
0.012x |
|
Akoya Biosciences Inc
NASDAQ:AKYA
|
1.225x |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
-0.056x |
|
HY Energy Group Co Ltd
SHG:600387
|
-0.044x |
|
Gohigh Data Networks Technology Co Ltd
SHE:000851
|
-0.007x |
|
Intermediate Capital Group PLC
LSE:ICG
|
-0.019x |
|
Wanshih Electronic Co Ltd
TWO:6134
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see PLRX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $181.21 Million | $-128.34 Million | -0.708x | -38.49% |
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more